Med Ed Report briefs

Share this article:
Genentech said last month that it would begin voluntarily disclosing data on its independent med-ed grants. Information covering the first quarter of 2010 will be followed by online reports issued quarterly.

Two universities enacted policies that restrict and quantify their medical faculty's potential role in industry activities—Harvard Medical School and the University of Minnesota.

KnowledgePoint360's Acumed unit opened larger offices in London and New York to accommodate business growth, the company said. Among four new additions was account manager Meghan Guercio (pictured above).

The 21st annual Conference of the National Task Force on CME Provider/Industry Collaboration, “Moving forward in an age of uncertainty; Creating innovative, practical educational solutions,” will be held Oct. 13-15 in Baltimore.

The National Commission for Certification of CME Professionals announced an Extension of Certification program for Certified CME Professionals when their current certificates expire. The EOC extends the initial three-year certification to five for candidates who meet requirements.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?